Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 19 of 19 entries
View as:

The Survey of Satisfaction in Chinese Rheumatologists and Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT03483597 Org: User:
Start: 03/31/18 End: 04/30/18 Due: 04/30/19

Kunxian for the Treatment of Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02764515 Org: User:
Start: 09/30/15 End: 11/30/17 Due: 11/30/18

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

Phase: N/A Priority: Normal
NCT ID: NCT05965284 Org: User:
Start: 03/09/23 End: 12/31/26 Due: 12/31/27

Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE

Phase: N/A Priority: Normal
NCT ID: NCT02444728 Org: User:
Start: 07/31/15 End: 12/30/18 Due: 12/30/19

Telitacicept for the Treatment of Refractory RA

Phase: N/A Priority: Normal
NCT ID: NCT07008196 Org: User:
Start: 06/10/25 End: 01/31/26 Due: 01/31/27

Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis

Phase: N/A Priority: Normal
NCT ID: NCT04737343 Org: User:
Start: 06/30/21 End: 12/31/24 Due: 12/31/25

Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT04582136 Org: User:
Start: 03/04/21 End: 05/01/25 Due: 05/01/26

Chinese Rheumatism Biobank(CRB)

Phase: N/A Priority: Normal
NCT ID: NCT06887517 Org: User:
Start: 02/10/25 End: 04/01/33 Due: 04/01/34

Anti-CD20 Antibodies for Treatment of SLE-PAH

Phase: N/A Priority: Normal
NCT ID: NCT05828147 Org: User:
Start: 05/25/23 End: 03/31/26 Due: 03/31/27

Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

Phase: N/A Priority: Normal
NCT ID: NCT05962840 Org: User:
Start: 06/29/23 End: 12/31/26 Due: 12/31/27

Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

Phase: N/A Priority: Normal
NCT ID: NCT05151848 Org: User:
Start: 01/05/22 End: 01/15/26 Due: 01/15/27

Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis

Phase: N/A Priority: Normal
NCT ID: NCT03096275 Org: User:
Start: 03/16/17 End: 11/11/22 Due: 11/11/23

Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT05805891 Org: User:
Start: 12/31/23 End: 12/31/25 Due: 12/31/26

Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT05916781 Org: User:
Start: 07/01/23 End: 07/31/26 Due: 07/31/27

Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis

Phase: N/A Priority: Normal
NCT ID: NCT05749666 Org: User:
Start: 01/20/23 End: 07/20/25 Due: 07/20/26

A Study on the Prevention and Treatment of GIOP With Eldecalcitol

Phase: N/A Priority: Normal
NCT ID: NCT06385093 Org: User:
Start: 06/30/24 End: 03/31/26 Due: 03/31/27

Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis

Phase: N/A Priority: Normal
NCT ID: NCT06167174 Org: User:
Start: 12/05/23 End: 12/05/28 Due: 12/05/29

The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

Phase: N/A Priority: Normal
NCT ID: NCT07013838 Org: User:
Start: 06/15/25 End: 03/31/28 Due: 03/31/29

Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT06881290 Org: User:
Start: 04/01/25 End: 04/01/27 Due: 04/01/28